{"id":"mfolfirinox-folfiri-intensified-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This regimen represents an escalated dosing strategy of standard FOLFIRI (fluorouracil, leucovorin, irinotecan) with the addition of oxaliplatin from the FOLFOX backbone. The combination targets multiple pathways: fluorouracil inhibits thymidylate synthase and incorporates into DNA/RNA; irinotecan inhibits topoisomerase I; and oxaliplatin forms DNA cross-links. The intensified approach aims to improve efficacy in advanced colorectal cancer.","oneSentence":"mFOLFIRINOX-FOLFIRI is an intensified chemotherapy regimen combining fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:07.667Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":406,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mFOLFIRINOX-FOLFIRI intensified chemotherapy","genericName":"mFOLFIRINOX-FOLFIRI intensified chemotherapy","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFIRINOX-FOLFIRI is an intensified chemotherapy regimen combining fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Metastatic colorectal cancer (phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}